Live feed07:00:00·814dPRReleasevia QuantisnowVOYDEYA™ approved in the US as add-on therapy to ravulizumab or eculizumab for treatment of extravascular hemolysis in adults with the rare disease PNHByQuantisnow·Wall Street's wire, on your screen.AZN· AstraZeneca PLCHealth Care
